1.92

0.26% 0.00

Proqr Therapeutics N V (PRQR)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$1.92

Offen:

$1.91

24-Stunden-Volumen:

578.04K

Relative Volume:

0.60

Marktkapitalisierung:

$270.95M

Einnahmen:

$15.53M

Nettoeinkommen (Verlust:

$-52.71M

KGV:

-3.8209

EPS:

-0.5025

Netto-Cashflow:

$-59.00M

1W Leistung:

+6.35%

1M Leistung:

+13.24%

6M Leistung:

+32.76%

1J Leistung:

-6.10%

1-Tages-Spanne:

$1.90

$2.00

1-Wochen-Bereich:

$1.79

$2.00

52-Wochen-Spanne:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Firmenname

Proqr Therapeutics N V

Sektor

Healthcare (1089)

Branche

Biotechnology (604)

Telefon

Adresse

Mitarbeiter

187

Twitter

@proqr

Nächster Verdiensttermin

2026-08-20

Neueste SEC-Einreichungen

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRQR Proqr Therapeutics N V	1.92	270.95M	15.53M	-52.71M	-59.00M	-0.5025
VRTX Vertex Pharmaceuticals Inc	515.43	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.92	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.25	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.31	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-12	Fortgesetzt	Oppenheimer	Outperform
2025-04-29	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-04-29	Eingeleitet	Evercore ISI	Outperform
2025-03-10	Hochstufung	Citigroup	Neutral → Buy
2025-01-10	Eingeleitet	Oppenheimer	Outperform
2024-10-29	Hochstufung	Raymond James	Outperform → Strong Buy
2023-11-08	Hochstufung	Chardan Capital Markets	Neutral → Buy
2023-03-30	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2022-12-22	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2022-02-14	Herabstufung	Citigroup	Buy → Neutral
2022-02-11	Herabstufung	Raymond James	Strong Buy → Mkt Perform
2022-02-11	Herabstufung	Stifel	Buy → Hold
2022-02-01	Eingeleitet	Raymond James	Strong Buy
2021-05-03	Eingeleitet	Stifel	Buy
2021-03-25	Bestätigt	Citigroup	Buy
2020-11-03	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-03-12	Bestätigt	Chardan Capital Markets	Buy
2018-12-19	Eingeleitet	RBC Capital Mkts	Outperform
2018-11-15	Eingeleitet	Citigroup	Buy
2018-09-19	Eingeleitet	Evercore ISI	Outperform
2017-09-26	Bestätigt	JMP Securities	Mkt Outperform
2016-06-20	Eingeleitet	Chardan Capital Markets	Neutral
2014-10-15	Eingeleitet	Deutsche Bank	Buy
2014-10-13	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten

07:46 AM

H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com India

07:46 AM

07:40 AM

H.C. Wainwright reiterates ProQR stock rating on platform data - Investing.com

07:40 AM

Aug 15, 2026

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria

Aug 14, 2026

Aug 13, 2026

ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 13, 2026

ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks

Aug 13, 2026

ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative

Aug 13, 2026

ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Aug 11, 2026

ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 11, 2026

Aug 07, 2026